Coral Laboratories Limited

BSE:524506 Stock Report

Market Cap: ₹2.8b

Coral Laboratories Valuation

Is 524506 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 524506 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524506 (₹779.7) is trading above our estimate of fair value (₹36.76)

Significantly Below Fair Value: 524506 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524506?

Key metric: As 524506 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 524506. This is calculated by dividing 524506's market cap by their current earnings.
What is 524506's PE Ratio?
PE Ratio12.2x
Earnings₹227.52m
Market Cap₹2.79b

Price to Earnings Ratio vs Peers

How does 524506's PE Ratio compare to its peers?

The above table shows the PE ratio for 524506 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average50.8x
SMSLIFE SMS Lifesciences India
13.9xn/a₹3.0b
543616 Trident Lifeline
32.6xn/a₹3.2b
ALPA Alpa Laboratories
14.4xn/a₹2.3b
524654 Natural Capsules
142.3xn/a₹3.1b
524506 Coral Laboratories
12.2xn/a₹2.8b

Price-To-Earnings vs Peers: 524506 is good value based on its Price-To-Earnings Ratio (12.2x) compared to the peer average (50.8x).

Price to Earnings Ratio vs Industry

How does 524506's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
INDSWFTLAB Ind-Swift Laboratories
1.6xn/aUS$70.43m
524652 Ind-Swift
2xn/aUS$13.12m
No more companies available in this PE range
524506 12.2xIndustry Avg. 31.6xNo. of Companies18PE020406080100+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 524506 is good value based on its Price-To-Earnings Ratio (12.2x) compared to the Indian Pharmaceuticals industry average (31.6x).

Price to Earnings Ratio vs Fair Ratio

What is 524506's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524506 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio12.2x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524506's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Vilin Bio Med

₹293.6m

Engages in the manufacture and sale of pharmaceutical products in India.

VILINBIO

₹21.05

7D

7.4%

1Y

-0.9%

Venus Remedies

₹3.9b

Engages in the pharmaceutical business in India and internationally.

VENUSREM

₹291.85

7D

-3.6%

1Y

-22.2%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹928.00

7D

-1.7%

1Y

15.6%